The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Alar Pharmaceuticals's Dividend Payout Ratio for the
months ended in Dec. 2025 was 0.00.
The historical rank and industry rank for Alar Pharmaceuticals's Dividend Payout Ratio or its related term are showing as below:
During the past 9 years, the highest Dividend Payout Ratio of Alar Pharmaceuticals was 5.56. The lowest was 5.56. And the median was 5.56.
ROCO:6785's Dividend Payout Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.38 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 12 months, Alar Pharmaceuticals's average Dividends Per Share Growth Rate was -83.30% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Alar Pharmaceuticals (ROCO:6785) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Alar Pharmaceuticals Dividend Payout Ratio Related Terms
Alar Pharmaceuticals Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6785 vs ZTS, UTHR: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Dividend Payout Ratio falls into.
Alar Pharmaceuticals Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Alar Pharmaceuticals's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alar Pharmaceuticals (ROCO:6785) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Alar Pharmaceuticals and its competitors. Over the past decade, Alar Pharmaceuticals' Dividend Payout Ratio has ranged from 5.56 to 5.56. According to the industry distribution chart, Alar Pharmaceuticals ranks #999999 out of 445 companies in the Drug Manufacturers industry.
Is Alar Pharmaceuticals' Dividend Payout Ratio too high?
Alar Pharmaceuticals' current Dividend Payout Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 5.56 to a high of 5.56. Based on the distribution chart, Alar Pharmaceuticals ranks #999999 out of 445 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Dividend Payout Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #999999 out of 445 companies for Dividend Payout Ratio. This places Alar Pharmaceuticals in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. Historically, Alar Pharmaceuticals' own Dividend Payout Ratio has ranged from 5.56 to 5.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 445 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Alar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$90.64, compared to a current price of NT$117.00 — trading 29.1% above its estimated fair value. The current Dividend Payout Ratio is 0.00. Alar Pharmaceuticals' overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$117.00 is trading 29.1% above its estimated GF Value™ of NT$90.64.
GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ROCO:6785:
Dividend Payout Ratio: 0.00
GF Value™: NT$90.64 vs. price of NT$117.00 (29.1% above fair value)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score
Get the complete analysis for ROCO:6785
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
